Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ligufalimab · AK117

Monoclonal antibody · Antagonist of CD47 · developed by Akeso

Phase 3 Most advanced trial

2 Registered trials

What is Ligufalimab?

Ligufalimab is a humanized IgG4 monoclonal antibody targeting CD47 on tumor cells. It blocks CD47 interaction with signal regulatory protein alpha on macrophages, preventing the inhibition of phagocytosis and promoting macrophage-mediated killing of cancer cells. It is being investigated in metastatic colorectal cancer and squamous cell carcinoma of the head and neck.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AK117
Drug type: Monoclonal antibody
Targets: CD47, signal regulatory protein alpha (SIRPA) (binding partner it blocks)
Mechanism: Antagonist of CD47
Pathways: macrophage activation, phagocytosis
Therapy area: Oncology
Developer: Akeso
In trials of: SMMT
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 1S4338NZB8

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07264075	Phase 3	Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)	Recruiting	SMMT
NCT05382442	Phase 2	Metastatic Colorectal Cancer	Active not recruiting	SMMT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Colorectal CancerSquamous Cell Carcinoma Head and Neck Cancer (HNSCC)

Other drugs acting on CD47

Evorpacept Phase 2/3 Spevatamig Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z